Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders

Maj Vinberg; Pernille Højman; Bente Klarlund Pedersen; Lars Vedel Kessing; Kamilla W Miskowiak

doi:10.1017/neu.2018.16

Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders

Maj Vinberg, Pernille Højman, Bente Klarlund Pedersen, Lars Vedel Kessing, Kamilla W Miskowiak

Institut for Klinisk Medicin

7 Citationer (Scopus)

Abstract

BACKGROUND: Erythropoietin (EPO) has been suggested to improve metabolism and also cognition, but human studies are scarce. This randomised controlled trial aimed to investigate whether EPO treatment influences body composition and fat and glycated haemoglobin (HbA1c) and fasting glucose, and whether these changes would be associated with previous observed cognitive benefits of EPO.

METHOD: In total, 84 non-obese patients with treatment-resistant unipolar depression or bipolar disorder in remission were randomised to 8 weekly EPO (40,000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Patients underwent dual X-ray absorptiometry scans at baseline and week 14 (6 weeks after treatment completion). Cognitive measures were assessed and fasting levels of cholesterol, lipoprotein fractions, triacylglycerides, glucose and HbA1c were obtained at baseline, week 9 and follow-up week 14.

RESULTS: In total, 79 patients had complete pre- and post-treatment data (EPO: N=40, saline: N=39). EPO had no cumulative effect on body composition and markers of fat metabolism. The EPO-treated group exhibited significantly lower HbA1c levels after 8 weeks treatment [F(1, 80)=8.51, p=0.005], however, 6 weeks after treatment termination a significantly higher fasting glucose levels [F(1, 79)=5.85, p=0.02] and HbA1c levels [F(1, 79)=5.85, p=0.02] were seen. The latter increase in HbA1c was further significantly correlated with a better cognitive outcome on verbal memory (r=0.25, p=0.03).

CONCLUSION: Repeated EPO infusions had no cumulative effect on body composition in this cohort of patients with affective disorders, however, EPO modulated HbA1c and fasting glucose and this was associated with patients' improvement of verbal memory.

Originalsprog	Engelsk
Tidsskrift	Acta Neuropsychiatrica
Vol/bind	30
Udgave nummer	6
Sider (fra-til)	342-349
Antal sider	8
ISSN	0924-2708
DOI	https://doi.org/10.1017/neu.2018.16
Status	Udgivet - 1 dec. 2018

Emneord

Det Samfundsvidenskabelige Fakultet

Adgang til dokumentet

10.1017/neu.2018.16

Citationsformater

@article{8d600b8ce53540fba4f58434f22499c9,

title = "Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders",

abstract = "BACKGROUND: Erythropoietin (EPO) has been suggested to improve metabolism and also cognition, but human studies are scarce. This randomised controlled trial aimed to investigate whether EPO treatment influences body composition and fat and glycated haemoglobin (HbA1c) and fasting glucose, and whether these changes would be associated with previous observed cognitive benefits of EPO.METHOD: In total, 84 non-obese patients with treatment-resistant unipolar depression or bipolar disorder in remission were randomised to 8 weekly EPO (40,000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Patients underwent dual X-ray absorptiometry scans at baseline and week 14 (6 weeks after treatment completion). Cognitive measures were assessed and fasting levels of cholesterol, lipoprotein fractions, triacylglycerides, glucose and HbA1c were obtained at baseline, week 9 and follow-up week 14.RESULTS: In total, 79 patients had complete pre- and post-treatment data (EPO: N=40, saline: N=39). EPO had no cumulative effect on body composition and markers of fat metabolism. The EPO-treated group exhibited significantly lower HbA1c levels after 8 weeks treatment [F(1, 80)=8.51, p=0.005], however, 6 weeks after treatment termination a significantly higher fasting glucose levels [F(1, 79)=5.85, p=0.02] and HbA1c levels [F(1, 79)=5.85, p=0.02] were seen. The latter increase in HbA1c was further significantly correlated with a better cognitive outcome on verbal memory (r=0.25, p=0.03).CONCLUSION: Repeated EPO infusions had no cumulative effect on body composition in this cohort of patients with affective disorders, however, EPO modulated HbA1c and fasting glucose and this was associated with patients' improvement of verbal memory.",

keywords = "Faculty of Social Sciences, body composition, cognition, erythropoietin, glucose, mood disorders, body composition, cognition, erythropoietin, glucose, mood disorders",

author = "Maj Vinberg and Pernille H{\o}jman and Pedersen, {Bente Klarlund} and Kessing, {Lars Vedel} and Miskowiak, {Kamilla W}",

year = "2018",

month = dec,

day = "1",

doi = "10.1017/neu.2018.16",

language = "English",

volume = "30",

pages = "342--349",

journal = "Acta Neuropsychiatrica",

issn = "0924-2708",

publisher = "Cambridge University Press",

number = "6",

}

TY - JOUR

T1 - Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders

AU - Vinberg, Maj

AU - Højman, Pernille

AU - Pedersen, Bente Klarlund

AU - Kessing, Lars Vedel

AU - Miskowiak, Kamilla W

PY - 2018/12/1

Y1 - 2018/12/1

N2 - BACKGROUND: Erythropoietin (EPO) has been suggested to improve metabolism and also cognition, but human studies are scarce. This randomised controlled trial aimed to investigate whether EPO treatment influences body composition and fat and glycated haemoglobin (HbA1c) and fasting glucose, and whether these changes would be associated with previous observed cognitive benefits of EPO.METHOD: In total, 84 non-obese patients with treatment-resistant unipolar depression or bipolar disorder in remission were randomised to 8 weekly EPO (40,000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Patients underwent dual X-ray absorptiometry scans at baseline and week 14 (6 weeks after treatment completion). Cognitive measures were assessed and fasting levels of cholesterol, lipoprotein fractions, triacylglycerides, glucose and HbA1c were obtained at baseline, week 9 and follow-up week 14.RESULTS: In total, 79 patients had complete pre- and post-treatment data (EPO: N=40, saline: N=39). EPO had no cumulative effect on body composition and markers of fat metabolism. The EPO-treated group exhibited significantly lower HbA1c levels after 8 weeks treatment [F(1, 80)=8.51, p=0.005], however, 6 weeks after treatment termination a significantly higher fasting glucose levels [F(1, 79)=5.85, p=0.02] and HbA1c levels [F(1, 79)=5.85, p=0.02] were seen. The latter increase in HbA1c was further significantly correlated with a better cognitive outcome on verbal memory (r=0.25, p=0.03).CONCLUSION: Repeated EPO infusions had no cumulative effect on body composition in this cohort of patients with affective disorders, however, EPO modulated HbA1c and fasting glucose and this was associated with patients' improvement of verbal memory.

AB - BACKGROUND: Erythropoietin (EPO) has been suggested to improve metabolism and also cognition, but human studies are scarce. This randomised controlled trial aimed to investigate whether EPO treatment influences body composition and fat and glycated haemoglobin (HbA1c) and fasting glucose, and whether these changes would be associated with previous observed cognitive benefits of EPO.METHOD: In total, 84 non-obese patients with treatment-resistant unipolar depression or bipolar disorder in remission were randomised to 8 weekly EPO (40,000 IU) or saline (NaCl 0.9%) infusions in a double-blind, parallel-group design. Patients underwent dual X-ray absorptiometry scans at baseline and week 14 (6 weeks after treatment completion). Cognitive measures were assessed and fasting levels of cholesterol, lipoprotein fractions, triacylglycerides, glucose and HbA1c were obtained at baseline, week 9 and follow-up week 14.RESULTS: In total, 79 patients had complete pre- and post-treatment data (EPO: N=40, saline: N=39). EPO had no cumulative effect on body composition and markers of fat metabolism. The EPO-treated group exhibited significantly lower HbA1c levels after 8 weeks treatment [F(1, 80)=8.51, p=0.005], however, 6 weeks after treatment termination a significantly higher fasting glucose levels [F(1, 79)=5.85, p=0.02] and HbA1c levels [F(1, 79)=5.85, p=0.02] were seen. The latter increase in HbA1c was further significantly correlated with a better cognitive outcome on verbal memory (r=0.25, p=0.03).CONCLUSION: Repeated EPO infusions had no cumulative effect on body composition in this cohort of patients with affective disorders, however, EPO modulated HbA1c and fasting glucose and this was associated with patients' improvement of verbal memory.

KW - Faculty of Social Sciences

KW - body composition

KW - cognition

KW - erythropoietin

KW - glucose

KW - mood disorders

KW - body composition

KW - cognition

KW - erythropoietin

KW - glucose

KW - mood disorders

U2 - 10.1017/neu.2018.16

DO - 10.1017/neu.2018.16

M3 - Journal article

C2 - 29880069

SN - 0924-2708

VL - 30

SP - 342

EP - 349

JO - Acta Neuropsychiatrica

JF - Acta Neuropsychiatrica

IS - 6

ER -

Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders

Abstract

Emneord

Adgang til dokumentet

Fingeraftryk

Citationsformater